JP2019535746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535746A5 JP2019535746A5 JP2019527358A JP2019527358A JP2019535746A5 JP 2019535746 A5 JP2019535746 A5 JP 2019535746A5 JP 2019527358 A JP2019527358 A JP 2019527358A JP 2019527358 A JP2019527358 A JP 2019527358A JP 2019535746 A5 JP2019535746 A5 JP 2019535746A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- cancer
- haloalkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(*)[C@](C(N(CCC1)[C@]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=*)=O)N*(C)=C Chemical compound CC(C)(*)[C@](C(N(CCC1)[C@]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=*)=O)N*(C)=C 0.000 description 2
- NFLUBBOGFHPRKD-UHFFFAOYSA-N CCC(C)(C=C)NCC Chemical compound CCC(C)(C=C)NCC NFLUBBOGFHPRKD-UHFFFAOYSA-N 0.000 description 1
- GGZXJZZUBNDABX-SSDOTTSWSA-N CCCN(CC1)C[C@@H]1O Chemical compound CCCN(CC1)C[C@@H]1O GGZXJZZUBNDABX-SSDOTTSWSA-N 0.000 description 1
- VLLRBPIIWLQFCD-UHFFFAOYSA-N Cc1c(-c2ccc(CNC)cc2)[s]cn1 Chemical compound Cc1c(-c2ccc(CNC)cc2)[s]cn1 VLLRBPIIWLQFCD-UHFFFAOYSA-N 0.000 description 1
- ONYGKYUQGHVRKU-RXMQYKEDSA-N NNCC(N(CC1)C[C@@H]1O)=O Chemical compound NNCC(N(CC1)C[C@@H]1O)=O ONYGKYUQGHVRKU-RXMQYKEDSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425211P | 2016-11-22 | 2016-11-22 | |
| US62/425,211 | 2016-11-22 | ||
| PCT/US2017/063027 WO2018098288A1 (en) | 2016-11-22 | 2017-11-22 | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535746A JP2019535746A (ja) | 2019-12-12 |
| JP2019535746A5 true JP2019535746A5 (enExample) | 2020-12-24 |
Family
ID=62195636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527358A Pending JP2019535746A (ja) | 2016-11-22 | 2017-11-22 | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10925967B2 (enExample) |
| EP (1) | EP3544959A4 (enExample) |
| JP (1) | JP2019535746A (enExample) |
| KR (1) | KR20190080956A (enExample) |
| AU (1) | AU2017363265B2 (enExample) |
| CA (1) | CA3042294A1 (enExample) |
| WO (1) | WO2018098288A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017117474A1 (en) * | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
| US10925967B2 (en) | 2016-11-22 | 2021-02-23 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| CN109422752B (zh) | 2017-09-03 | 2023-04-07 | 上海美志医药科技有限公司 | 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物 |
| JP2021512059A (ja) * | 2018-01-29 | 2021-05-13 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
| WO2019170150A1 (zh) | 2018-03-09 | 2019-09-12 | 上海科技大学 | 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用 |
| CN118754858A (zh) | 2018-03-26 | 2024-10-11 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| US12582641B2 (en) | 2019-02-25 | 2026-03-24 | Shanghaitech University | Sulfur-containing compound based on glutarimide skeleton and application thereof |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
| CN110204532B (zh) * | 2019-05-15 | 2022-03-08 | 浙江工业大学 | 一种靶向egfr蛋白降解的化合物及其制备方法和应用 |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| CN114174299B (zh) * | 2019-07-26 | 2024-10-25 | 百济神州有限公司 | 通过btk抑制剂与e3连接酶配体缀合对布鲁顿氏酪氨酸激酶(btk)的降解以及使用方法 |
| CN112321566B (zh) * | 2019-08-05 | 2022-06-10 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| CN114521196A (zh) * | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| WO2021058017A1 (en) * | 2019-09-29 | 2021-04-01 | Beigene, Ltd. | Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use |
| US12310975B2 (en) | 2019-10-17 | 2025-05-27 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CN114478532A (zh) * | 2020-10-26 | 2022-05-13 | 上海美志医药科技有限公司 | 靶向降解Btk的化合物及其抗肿瘤用途 |
| CN116981675A (zh) * | 2020-12-31 | 2023-10-31 | 百济神州有限公司 | 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| CA3214806A1 (en) | 2021-04-16 | 2022-10-20 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| WO2023137225A1 (en) * | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Btk degrader |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2015106292A1 (en) * | 2014-01-13 | 2015-07-16 | Coferon, Inc. | Bcr-abl tyrosine-kinase ligands capable of dimerizing in an aqueous solution, and methods of using same |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| TW201701879A (zh) * | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| WO2017117474A1 (en) * | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
| US10925967B2 (en) * | 2016-11-22 | 2021-02-23 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
-
2017
- 2017-11-22 US US16/343,979 patent/US10925967B2/en active Active
- 2017-11-22 WO PCT/US2017/063027 patent/WO2018098288A1/en not_active Ceased
- 2017-11-22 JP JP2019527358A patent/JP2019535746A/ja active Pending
- 2017-11-22 EP EP17873156.8A patent/EP3544959A4/en not_active Withdrawn
- 2017-11-22 KR KR1020197018106A patent/KR20190080956A/ko not_active Withdrawn
- 2017-11-22 AU AU2017363265A patent/AU2017363265B2/en active Active
- 2017-11-22 CA CA3042294A patent/CA3042294A1/en active Pending
-
2020
- 2020-12-16 US US17/123,955 patent/US11730818B2/en active Active
-
2023
- 2023-06-27 US US18/214,825 patent/US12329821B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535744A5 (enExample) | ||
| JP2021512059A5 (enExample) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2013522292A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| JP2020007311A5 (enExample) | ||
| JP2022547952A5 (enExample) | ||
| CN114430741A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2021522166A5 (enExample) | ||
| CN115605479A (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2021534168A5 (enExample) | ||
| JP2018510191A5 (enExample) | ||
| RU2018119173A (ru) | Производное бензофурана, способ его получения и его применение в медицине | |
| JP2018516917A5 (enExample) | ||
| JP2018504418A5 (enExample) | ||
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2011509309A5 (enExample) | ||
| JP2018505880A5 (enExample) | ||
| RU2016130986A (ru) | Ингибитор киназы и его применение | |
| JP2017533266A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2020536971A5 (enExample) | ||
| JP2019514876A5 (enExample) |